Heutzutage ist die soziale Arbeit eine große Herausforderung für die koreanische Kirche. Die Diakonia ist neben der Koinonia, der martyria und der leiturgia eine Grundfunktion kirchlichen Handelns. In den koreanischen Gemeinden spielt aber die Diakonia eine eigentümlich untergeordnete Rolle. Daher beschäftigt sich diese Arbeit mit dem Thema Soziale Arbeit, mit ihren theologischen Begründungen und mit einem exemplarischen Handlungsfeld. In der Arbeit werden zuerst die Menschenwürde und die Menschenrechte dargestellt. Im Anschluss werden die biblischen Begründungen, die wichtigsten kirchengeschichtlichen und gesellschaftliche Entwicklungen thematisiert. Schließlich wird ein exemplarisches Handlungsfeld der sozialen Arbeit im deutsch-koreanischen Vergleich dargestellt. Die Integrationsarbeit der evangelischen Diakonie in Deutschland kann wesentliche Impulse für ein vertieftes Engagement der koreanischen Gemeinden für Arbeitsmigranten in Korea geben.
STATES HAVE CHOSEN VARIOUS INTERNATIONAL FORA TO NEGOTIATE ON THE DISCIPLINING OF STATE AIDS THROUGH EXPORT CREDIT INSURANCE: THE GATT, EUROPEAN UNION (EU) AND THE OECD. ALTHOUGH ON A GLOBAL LEVEL THE VIOLATION OF THE STRICT GATT RULES ON EXPORT CREDIT INSURANCE COULD BE IGNORED, ON THE REGIONAL EU LEVEL, MARKET INTEGRATION AND COMPETITION AND COMMON COMMERCIAL POLICIES CREATED PRESSURES TO HARMONIZE NATIONAL CREDIT INSURANCE POLICIES. IN THE RESULTING REGIONAL NEGOTIATING PRECESS, INTERGOVERNMENTAL FACTORS HAVE PREVAILED OVER SUPRANATIONAL/TRANSNATIONAL FACTORS. NEITHER TRANSNATIONAL INTEREST GROUPS NOR THE EUROPEAN PARLIAMENT AND THE COMMISSION HAVE BEEN IMPORTANT ACTORS IN THIS PROCESS. THE REAL POLTIICLA ISSUE OF COMPETITION DISTORTION BETWEEN EXPORTERS OF DIFFERENT MEMBER STATES HAS BEEN TAKEN CARE OF BY THE MEMBER STATES IN A SPECIAL O-ORDINATION GROUP, SET UP BY THE COUNCIL. ALTHOUGH NATIONAL PREFERENCES WITH REGARD TO HARMONIZING OFFICIAL CREDIT INSURANCE POLICY HAVE CONVERGED AS A CONSEQUENCE OF RISING CUMULATIVE DEFICITS ON THESE INSURANCE SCHEMES IN ALL MEMBER STATES AND THE PRESSURE OF MARKET FACTORS SUCH AS INCREASING CROSS-BORDER COOPERATION, THE HARMONIZATION PROCESS APPEARS TO BE CONFINED TO TRANSPARENCY AND HARMONIZATION OF INSURANCE TECHNIQUES AND LIMITED CO-OPERATION AMONG PUBLIC INSURERS IN THE CASE OF CONSORTIUM EXPORTS.
Political Science - Nederland is nodig toe aan democratische zelfreflectie. Ingrijpende maatschappelijke ontwikkelingen als de verplaatsing van de politiek, mediatsering, Europese integratie, mondialisering, vervreemde burgers en toenemende maatschappelijke complexiteit nopen hiertoe. Maar ook de electorale aardverschuiving van mei 2002 en de recente initiatieven van de minister voor Bestuurlijke Vernieuwing leiden tot veel discussie over de staat van de democratie en 'democratische vernieuwing'. Wat is er aan de hand? En, belangrijker nog, wat is er aan te doen? In deze WRR-verkenning analyseert en beoordeelt een reeks van deskundigen afkomstig uit de wetenschap, beleid en veld deze uitdagingen aan de democratie. Vervolgens belicht een viertal democratie-experts wat democratische benaderingen voor oplossingen te bieden hebben. Moet het primaat weer bij de politiek worden gelegd, is het referendum het antwoord, is interactief bestuur het panacee of moeten we juist vertrouwen op het vermogen tot zelfbestuur van maatschappelijke organisaties.
Political Science; European Union - De serie 'Werkdocumenten' omvat stukken die in het kader van de werkzaamheden van de WRR tot stand zijn gekomen en die op aanvraag door de raad beschikbaar worden gesteld. De verantwoordelijkheid voor de inhoud en de ingenomen standpunten berust bij de auteurs.
Political Science; European Union - De serie 'Werkdocumenten' omvat stukken die in het kader van de werkzaamheden van de WRR tot stand zijn gekomen en die op aanvraag door de raad beschikbaar worden gesteld. De verantwoordelijkheid voor de inhoud en de ingenomen standpunten berust bij de auteurs.
Gives an introduction to the market for export credit insurance; outlines governments' motives for entering this market and the regulations which already exist at the global level in order to keep this support in check. Examines the disciplining initiatives and development in this issue area within the EU. Examines which strategies have been chosen in the case of state aids through credit insurance and which factors have dominated this process. Describes the interaction between policymaking at the regional and global levels. Unhappy with progress in Europe, the UK decided to bring the credit insurance issue to the OECD.
Cellular immunological assays are important tools for the monitoring of responses to T-cell-inducing vaccine candidates. As these bioassays are often technically complex and require considerable experience, careful technology transfer between laboratories is critical if high quality, reproducible data that allows comparison between sites, is to be generated. The aim of this study, funded by the European Union Framework Program 7-funded TRANSVAC project, was to optimise Standard Operating Procedures and the technology transfer process to maximise the reproducibility of three bioassays for interferon-gamma responses: enzyme-linked immunosorbent assay (ELISA), ex-vivo enzyme-linked immunospot and intracellular cytokine staining. We found that the initial variability in results generated across three different laboratories reduced following a combination of Standard Operating Procedure harmonisation and the undertaking of side-by-side training sessions in which assay operators performed each assay in the presence of an assay 'lead' operator. Mean inter-site coefficients of variance reduced following this training session when compared with the pre-training values, most notably for the ELISA assay. There was a trend for increased inter-site variability at lower response magnitudes for the ELISA and intracellular cytokine staining assays. In conclusion, we recommend that on-site operator training is an essential component of the assay technology transfer process and combined with harmonised Standard Operating Procedures will improve the quality, reproducibility and comparability of data produced across different laboratories. These data may be helpful in ongoing discussions of the potential risk/benefit of centralised immunological assay strategies for large clinical trials versus decentralised units.
A voluntary immunization programme to prevent perinatal transmission of hepatitis B virus (HBV) infection in Singapore was implemented on 1 October 1985 as an integral component of the national childhood immunization programme. Up to April 1988, a total of 68,845 mothers who attended government maternal and child health clinics were screened for the disease. Of these, 2432 (3.5%) were positive for hepatitis B surface antigen (HBsAg) and 904 (1.3%) for hepatitis B e antigen (HBeAg). Virtually all the babies born to carrier mothers completed the full immunization schedule; and in addition, those of HBeAg-positive mothers were given a dose of hepatitis B immunoglobulin at birth. The hepatitis B immunization programme was extended on 1 September 1987 to cover all newborns. About 90% of the 15,943 babies delivered in government institutions from September 1987 to April 1988 were immunized at birth, with the subsequent doses being administered at maternal and child health clinics at 4-6 weeks and 5 months later. More than 85% of the children given the full course of plasma-derived and yeast-derived hepatitis B vaccine from birth continued to have protective antibody to HBV two years after immunization. The programme is being closely monitored to assess the duration of immunity and the need for booster doses, while seronegative adults are also being encouraged to be vaccinated.
Rubella virus (RV)-specific immunoglobulin G (IgG) antibodies were studied in military recruits undergoing unselected immunization with live attenuated measles, mumps, and rubella virus (MMR) vaccine. Three different whole-RV enzyme immunoassays (EIAs) and an epitope-specific EIA with a synthetic peptide (BCH-178c) representing a heutralization domain on the RV E1 envelope protein were used. Before vaccination, 84.2, 87.7, and 84.5% of the subjects tested (n = 399) were found to be seropositive (> 10 IU/ml or assay equivalent) by the three whole-RV EIAs, respectively, while only 82.5% were seropositive by the BCH-178c EIA. Although prevaccination seropositivity rates were similar for the whole-RV EIAs (sensitivity, 94 to 100%), many sera considered seropositive by the whole-RV EIAs had E1 peptide EIA antibody levels of 10 IU/ml. After vaccination, depending on the assay used, up to 20.6% of initially seropositive individuals exhibited a greater than fourfold increase in RV-specific IgG, while up to 47.3% showed a greater than twofold increase. Increased antibody titers after vaccination (seroboosting) were most frequently associated with low levels of BCH-178c peptide-specific IgG before vaccination. RV protein-specific IgG was also studied by immunoblot assays in a subset (n = 56) of individuals receiving the MMR vaccine. Of these, 89.4 and 91.1% exhibited RV protein (E1, E2, and C protein)-specific IgG before and after vaccination, respectively. Seroboosting (two- to fourfold increase in EIA titers of individuals seropositive by the whole-RV EIA before vaccination) was usually accompanied by a shift in the IgG immunoblot pattern from a single (E1) to multiple (E1-E1, E1-C, or E1-E2-C) specificities, suggesting exposure of new epitopes as a result of ...
Background Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. Methods This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Findings Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11 827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Interpretation Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long-term investment in surge capacity for acute care during public health emergencies to protect elective staff and services. Funding National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.
Background Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. Methods This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Findings Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Interpretation Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long- term investment in surge capacity for acute care during public health emergencies to protect elective staff and services. Funding National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.